These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 15507217)

  • 41. A molecular analysis of vesicular amine transport.
    Liu Y; Peter D; Merickel A; Krantz D; Finn JP; Edwards RH
    Behav Brain Res; 1996; 73(1-2):51-8. PubMed ID: 8788477
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug interactions with vesicular amine transport.
    Peter D; Jimenez J; Liu Y; Merickel A; Krantz D; Edwards RH
    NIDA Res Monogr; 1996; 161():176-200. PubMed ID: 8784851
    [No Abstract]   [Full Text] [Related]  

  • 43. The neuroprotective role of vesicular monoamine transporter 2 in neurodegenerative diseases.
    Yulug B; Hanoglu L; Kilic E
    Med Chem; 2015; 11(2):104-8. PubMed ID: 25256242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein.
    Truong JG; Newman AH; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2004 Nov; 504(1-2):27-32. PubMed ID: 15507217
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of psychostimulants on vesicular monoamine transporter function.
    Fleckenstein AE; Hanson GR
    Eur J Pharmacol; 2003 Oct; 479(1-3):283-9. PubMed ID: 14612158
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulation of vesicular neurotransmitter transporters.
    Ahnert-Hilger G; Höltje M; Pahner I; Winter S; Brunk I
    Rev Physiol Biochem Pharmacol; 2003; 150():140-60. PubMed ID: 14517724
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vesicular integrity in Parkinson's disease.
    Alter SP; Lenzi GM; Bernstein AI; Miller GW
    Curr Neurol Neurosci Rep; 2013 Jul; 13(7):362. PubMed ID: 23690026
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.
    Fleckenstein AE; Volz TJ; Hanson GR
    Neuropharmacology; 2009; 56 Suppl 1(Suppl 1):133-8. PubMed ID: 18662707
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent advances in dopamine D
    Juza R; Musilek K; Mezeiova E; Soukup O; Korabecny J
    Med Res Rev; 2023 Jan; 43(1):55-211. PubMed ID: 36111795
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.